SCHEMBL3944231

SCHEMBL3944231

CC(C)(C)c1ccc(S(=O)(=O)Nc2ccc3[nH]c(C(=O)NCCN4CCOCC4)c(-c4csc5ccccc45)c3c2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.44
ALDH1A1 P00352 7/20 0.43
CYP1A2 P05177 3/20 0.43
CYP2D6 P10635 3/20 0.43
CYP2C9 P11712 3/20 0.43
CYP2C19 P33261 3/20 0.43
CYP3A4 P08684 2/20 0.43
HTR6 P50406 2/20 0.40
KDM4E B2RXH2 4/20 0.39
PKM P14618 1/20 0.39
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39
KMT2A Q03164 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
LMNA P02545 1/20 0.38
PARP1 P09874 2/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
MDM4 O15151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3946688 0.89 BRD4 (0.42) BRD4ALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL3945336 0.89 ALDH1A1 (0.46) BRD4ALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL3944355 0.88 ALDH1A1 (0.45) BRD4ALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL3943840 0.88 ALDH1A1 (0.47) BRD4ALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL3951945 0.87 CD274 (0.50) BRD4ALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL3947120 0.86 ALDH1A1 (0.45) BRD4ALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL3942350 0.86 ALDH1A1 (0.43) BRD4ALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL3951642 0.86 ALDH1A1 (0.44) BRD4ALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL3943287 0.85 WNT1 (0.49) BRD4ALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL3942340 0.85 ALDH1A1 (0.45) BRD4ALDH1A1CYP1A2CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1802572-B1 INDOL DERIVATIVES AS INHIBITORS OF SOLUBLE ADENYLYL CYCLASE BAYER SCHERING PHARMA AG (DE) 2009-04-22 EP claimed
US-20080004268-A1 INHIBITORS OF SOLUBLE ADENYLATE CYCLASE NGUYEN DUY 2008-01-03 US disclosed
US-20080004268-A1 INHIBITORS OF SOLUBLE ADENYLATE CYCLASE NGUYEN DUY 2008-01-03 US disclosed
US-20060074084-A1 Inhibitors of soluble adenylate cyclase BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004268-A1 INHIBITORS OF SOLUBLE ADENYLATE CYCLASE ADCY1, ADCY2, ADCY5 BRD4 3928/4885ALDH1A1 268/4885CYP1A2 1151/4885
US-20060074084-A1 Inhibitors of soluble adenylate cyclase ADCY1, ADCY2, ADCY5 BRD4 3928/4885ALDH1A1 268/4885CYP1A2 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.